BLCM News and Press, Bellicum Pharmaceuticals Inc. From 01/29/21

Siebert Financial (SIEB) +453%.LM Funding America (LMFA) +101%.GameStop (GME) +75%.Koss Corporation (KOSS) +63%.Novavax (NVAX) +60% as its COVID-19 vaccine shows 89% efficacy in UK, 60% in South Africa.Catabasis Pharmaceuticals (CATB) +51% after announcing acquisition of Quellis Bio...

Bellicum Pharma ([[BLCM]] -1.0%) announces that the U.S. FDA has lifted the clinical hold on patient enrollment and dosing in its Phase 1/2 dose-escalation clinical trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic pancreatic or prostate cancer.The company ...

HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on patient enrollment and d...

Bellicum Pharmaceuticals (BLCM) has announced enrollment and apheresis of the first patient in Phase 1/2 trial for BPX-603 in patients with solid tumors that express human epidermal growth factor 2.The trial will investigate the safety, tolerability, and activity of BPX-603, adminis...

HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment and apheresis of the first patient in the Phase 1/2 clinical trial for BPX-603 in patients wit...

Bellicum Pharmaceuticals (BLCM) slides 12% in premarket as the FDA has placed a clinical hold on enrollment and dosing in Phase 1/2 study evaluating BPX-601, a GoCAR-T candidate, in patients with previously treated metastatic pancreatic or prostate cancer, after the d...

HOUSTON, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has been notified by the U.S. Food and Drug Administration (FDA) that a clinical hold has been pl...

Bellicum Pharmaceuticals (BLCM): Q3 GAAP EPS of -$0.18.Cash and cash equivalents of $53.1MShares +1.05% AH.Press Release For further details see: Bellicum Pharmaceuticals reports Q3 results

Strategic focus on clinical GoCAR-T ® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year Completed offering of shares of common stock plus warrants that raised gross proceeds of approximately...

HOUSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing of its underwritten offering of 1,040,000 shares of common stock, pre-funded warrants to purc...